Doxazosin Mesylate

Base Information

• Chemical Name: Doxazosin Mesylate
• CAS No.: 77883-43-3
• Molecular Formula: C24H29N5O8S
• Molecular Weight: 547.58
• Hs Code.: 2934.90
• European Community (EC) Number: 616-536-9,643-013-2
• NSC Number: 759284
• UNII: 86P6PQK0MU
• DSSTox Substance ID: DTXSID5045598
• Wikidata: Q27106443
• NCI Thesaurus Code: C29005
• RXCUI: 39173
• ChEMBL ID: CHEMBL1200561
• Mol file: 77883-43-3.mol

Synonyms:1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine;Alfamedin;Apo Doxazosin;Apo-Doxazosin;Cardular;Cardura;Carduran;Carduran Neo;ct, doxazosin von;Diblocin;Doxa Puren;Doxa-Puren;Doxacor;Doxagamma;Doxamax;Doxatensa;DoxaUro;Doxazomerck;Doxazosin;Doxazosin AL;Doxazosin Apogepha;Doxazosin AZU;Doxazosin beta;Doxazosin findusFit;Doxazosin Heumann;Doxazosin Klast;Doxazosin Mesylate;Doxazosin Monohydrochloride;Doxazosin ratiopharm;Doxazosin Stada;doxazosin von ct;Doxazosin Wolff;Doxazosin-ratiopharm;Doxazosin-Wolff;Doxazosina Alter;Doxazosina Cinfa;Doxazosina Combino Pharm;Doxazosina Geminis;Doxazosina Normon;Doxazosina Pharmagenus;Doxazosina Ratiopharm;Doxazosina Ur;Gen Doxazosin;Gen-Doxazosin;Jutalar;Mesylate, Doxazosin;Monohydrochloride, Doxazosin;MTW Doxazosin;MTW-Doxazosin;Neo, Carduran;Novo Doxazosin;Novo-Doxazosin;Progandol Neo;ratio Doxazosin;ratio-Doxazosin;Ratiopharm, Doxazosina;UK 33274;UK-33274;UK33274;Uriduct;von ct, doxazosin;Zoxan

Chemical Property of Doxazosin Mesylate

Chemical Property:

• Appearance/Colour: White crystalline powder
• Melting Point: 275-277 °C
• Boiling Point: 718 °C at 760 mmHg
• Flash Point: 388 °C
• PSA: 175.02000
• LogP: 2.88670
• Storage Temp.: Desiccate at RT
• Solubility.: Slightly soluble in water, soluble in a mixture of 15 volumes of water and 35 volumes of tetrahydrofuran, slightly soluble in methanol, practically insoluble in acetone. It shows polymorphism (5.9), some forms may be hygroscopic
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 12
• Rotatable Bond Count: 4
• Exact Mass: 547.17368407
• Heavy Atom Count: 38
• Complexity: 770

Purity/Quality:

99%+ ^*data from raw suppliers

Doxazosin mesylate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37-24/25

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O
• Recent EU Clinical Trials: A proof of concept study in allergic rhinitis, to evaluate the differential effects of doxazosin between single and chronic dosing on nasal airway calibre
• Description: Doxazosin mesylate is a quinazoline compound that is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. The chemical name of doxazosin mesylate is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate.The empirical formula for doxazosin mesylate is C23H25N505 ? CH4O3S and the molecular weight is 547.6. Doxazosin mesylate is freely soluble in dimethylsulfoxide, soluble in dimethylformamide, slightly soluble in methanol, ethanol, and water (0.8% at 25°C), and very slightly soluble in acetone and methylene chloride. Each doxazosin mesylate tablet, for oral administration, contains 1 mg, 2 mg, 4 mg and 8 mg of doxazosin as the free base. Doxazosin mesylate is a new generation of quinazolone α1 receptor blocker developed by the Pfizer company (United States), It has a long half-life, exerting its effects of dilating the blood vessels, reducing the vascular resistance and lowering the blood pressure through blocking the a 1 receptor. It selectively blocks the a1 adrenergic receptor of the prostate smooth muscle matrix, capsule and bladder neck, alleviating the symptoms of patients of benign prostatic hyperplasia, while having good curing effect on the dysuria caused by simple prostatic hyperplasia. In 1988, doxazosin, as a drug for the treatment of hypertension, had been listed in Denmark. In 1995, the US FDA had approved it for the treatment of benign prostatic hyperplasia. In 2002 September, Doxazosin controlled release tablets had been listed in China, providing a new option for the domestic treatment of benign prostatic hyperplasia. It has been recommended abroad as first-line clinical drugs of anti-hypertension and treatment of prostate disease.
• Uses: A selective α-1-adrenergicblocker related to prazosin. antihypertensive Doxazosin is a selective α1-adrenoceptor antagonist. Doxazosin relaxes smooth muscles of the prostate. Doxazosin ER is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia A selective a-1-adrenergicblocker related to prazosin